|

Fianlimab 1600 MG Intravenous Solution Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • University of Oklahoma1

Indications

  • Clear Cell Renal Cell Carcinoma1
  • Cancer1

Oklahoma City, Oklahoma1 trial

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

University of Oklahoma Health Sciences Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.